格隆汇1月6日丨永安药业(002365.SZ)公布，为优化管理架构，提高运营效率，降低管理成本，整合优 质资源，潜江永安药业股份有限公司拟对全资子公司湖北凌安科技有限公司（简称"凌安科技"）进行吸 收合并，合并完成后，凌安科技将予以注销，其全部资产、债权、债务、业务、人员及其他一切权利与 义务等由公司依法承继。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：300080 证券简称：易成新能 公告编号：2025－120 河南易成新能源股份有限公司 关于吸收合并全资子公司开封恒锐新金刚石制品有限公司的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、交易概述 河南易成新能源股份有限公司（以下简称"公司"）于2025年12月30日召开了第七届董事会第一次会议， 审议通过了《关于吸收合并全资子公司开封恒锐新金刚石制品有限公司的议案》，为提高运营效率、降 低管理成本，进一步优化资源配置，公司拟吸收合并全资子公司开封恒锐新金刚石制品有限公司（以下 简称"恒锐新"），吸收合并完成后，恒锐新依法注销，其全部业务、资产、债权、债务等由公司依法继 承。 本次吸收合并是在原合并报表范围内的合并，本事项不构成关联交易，也不构成《上市公司重大资产重 组管理办法》规定的重大资产重组。本次吸收合并不涉及公司注册资本等事项的变更。根据《深圳证券 交易所创业板股票上市规则》和《公司章程》的相关规定，本次事项不涉及支付对价，本次吸收合并事 项尚需提交公司股东会审议。 成立时间：19 ...

格隆汇12月30日丨常山药业(300255.SZ)公布，为进一步优化公司资产配置，降低管理成本，拟以公司 为主体吸收合并全资子公司河北梅山多糖多肽科技有限公司（简称梅山科技）。吸收合并完成后，梅山 科技将依法注销，梅山科技全部业务、资产、债权、债务及其他一切权利和义务由公司依法承继。 ...

南网数字公告称，2024年12月30日公司董事会同意由全资子公司数字电网科技公司吸收合并全资子公司 昆明能讯。近日，昆明能讯工商注销登记手续办理完毕，其全部资产、债权、债务等由数字电网科技公 司依法承继。本次吸收合并有利于优化公司管理架构，降低成本、提高效率，且不会对公司财务状况产 生实质影响，符合公司及全体股东利益。 ...

证券代码：600768 证券简称：宁波富邦 公告编号：临2025-065 宁波富邦精业集团股份有限公司 二、吸收合并对公司的影响 的公告 公司本次吸收合并贸易公司，有利于公司组织架构的进一步优化，降低管理成本，提高运营效率，符合 公司发展战略。贸易公司为公司的全资子公司，其财务报表已纳入公司的合并报表范围，本次吸收合并 不会对公司财务状况产生实质影响，不会影响公司后续业务发展和持续盈利能力，符合公司及全体股东 的利益。 特此公告。 宁波富邦精业集团股份有限公司董事会 2025年12月20日 一、吸收合并进展情况 近日，公司取得了宁波市江北区市场监督管理局出具的《登记通知书》，公司吸收合并贸易公司的相关 工商手续已办理完毕，贸易公司已完成注销登记。本次吸收合并事项完成后，贸易公司全部资产、债权 债务及其他一切权利和义务均由公司依法承继。 关于完成吸收合并全资子公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 宁波富邦精业集团股份有限公司（以下简称"公司"）分别于2025年5月29日、2025年6月27日召开十届董 事会 ...

格隆汇12月8日丨甘咨询(000779.SZ)公布，甘肃省城乡规划设计研究院有限公司（简称"城乡规划院"） 系甘肃工程咨询集团股份有限公司全资子公司西部（甘肃）规划咨询有限公司的全资子公司。甘肃万源 岩土工程有限公司（简称"万源岩土公司"）为城乡规划院的全资子公司。城乡规划院为发挥资源优势、 提高运营效率、降低管理成本，拟整合其所属业务资源，以自身为主体吸收合并万源岩土公司。吸收合 并完成后，城乡规划院将继续存续，万源岩土公司将依法注销，其全部业务、资产、债权及债务由城乡 规划院依法承继。 ...

Core Viewpoint - The company, AVIC Harbin Aircraft Industry Group Co., Ltd. (哈飞集团), plans to absorb and merge its wholly-owned subsidiary, Harbin Hafei Aviation Industry Co., Ltd. (哈飞航空), to optimize its organizational structure [1] Group 1: Merger Details - The merger will result in Harbin Hafei Aviation losing its independent legal status, with all assets, liabilities, long-term equity investments, personnel, and business being transferred to Harbin Aircraft [1] - After the merger, Harbin Aircraft's registered capital will change to 303,804.85 million yuan [1] Group 2: Strategic Benefits - The merger is expected to enhance the combined entity's capabilities in equity management, asset integration, cost collection, R&D investment, equipment manufacturing qualifications, and confidentiality [1] - This consolidation aims to unify the core functions and capabilities of different entities within the company, thereby optimizing the organizational structure [1]

Core Viewpoint - The company announced the absorption merger of its wholly-owned subsidiary Ningbo Xinfly, which has been approved by the board and shareholders, aiming to optimize organizational management, improve operational efficiency, and reduce management costs without materially affecting the company's financial status [1] Group 1 - The merger is scheduled for October 2024, with a merger agreement signed in June 2025, establishing June 30 as the merger reference date [1] - The company has received a notice of approval for the cancellation of registration, indicating that the business cancellation procedures for Ningbo Xinfly have been completed [1] - The absorption merger is expected to enhance the company's management structure and operational efficiency [1]

Core Points - The company has completed the absorption merger of its wholly-owned subsidiary Guosheng Securities Co., Ltd. and has changed its name to Guosheng Securities Co., Ltd. [4][8][12] - The company reported a net profit impact of -162 million yuan due to changes in accounting methods for its equity investment in Qudian [4][5] - The company held its first extraordinary general meeting of 2025, where it elected a new board of directors and appointed senior management [5][43] Financial Data - The company confirmed that there were no adjustments or restatements of previous accounting data [1] - Non-recurring gains and losses included a VAT exemption, with a total of -4.2231 million yuan recognized as regular gains and losses due to idle fund management [2][3] - The third-quarter financial report was not audited [1][7] Shareholder Information - The company has not reported any changes in the number of shareholders or major shareholders participating in securities lending [3] Other Important Matters - The company has received approval from the China Securities Regulatory Commission for the merger and will disclose financial statements according to the Ministry of Finance's requirements for securities financial enterprises after the merger [4][12] - The company has established four specialized committees under the new board of directors: Strategy Committee, Nomination and Remuneration Committee, Audit Committee, and Risk Control Committee [46][47] - The company has appointed new senior management, including Zhao Jingliang as General Manager and Zhang Changsheng as Vice General Manager and CFO [48][49]

Core Viewpoint - Kanghong Pharmaceutical (002773.SZ) has completed the absorption merger with Beijing Hongjian, which is expected to enhance operational efficiency, optimize resource allocation, and reduce management costs, aligning with the company's development strategy [1] Group 1: Merger Details - Beijing Hongjian has received the registration and cancellation approval from the Beijing Economic and Technological Development Zone Market Supervision Administration, confirming the completeness and legality of the cancellation application [1] - Following the merger, Beijing Kanghong Bio will continue to operate under the same name, shareholding structure, business scope, and registered capital [1] Group 2: Financial Impact - The financial statements of both the merging and merged entities have been included in the company's consolidated financial statements, indicating that the merger will not have a substantial impact on the consolidated financial reports [1] - The merger is not expected to adversely affect the company's overall business development and sustainable profitability, nor will it harm the interests of the company and its shareholders, particularly minority shareholders [1] Group 3: Ongoing Processes - As of now, Sichuan Jishengtang Xingshang Biotechnology Co., Ltd. and Beijing Hongjian have completed their cancellation processes, while Sichuan Kanghong Traditional Chinese Medicine Planting Co., Ltd. is in the process of merging with Chengdu Kanghong Pharmaceutical Trading Co., Ltd. [1]